Clinical Trial Update: Phase III Study of AK112 for NSCLC Patients [Phase 3]

View source ↗

Summary

This document provides an update on a Phase III trial of AK112 for non-small cell lung cancer. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AK112

Snippet

Sponsor: Summit Therapeutics | Conditions: Non-Squamous Non-small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING